Last updated: September 7, 2026
Doxepin hydrochloride is a mature generic pharmaceutical with three commercial markets: oral capsules and tablets for depression and anxiety, low-dose oral tablets for insomnia, and topical cream for pruritus and atopic dermatitis. The base molecule has no meaningful remaining composition-patent protection. Commercial value is concentrated in generic volume, low-dose insomnia formulations, topical dermatology products, and branded or authorized-generic distribution rather than in a single protected franchise.
Standalone revenue for doxepin hydrochloride is not publicly disclosed by major manufacturers. The market is fragmented across generic suppliers, pharmacy wholesalers, private-label products, and specialty dermatology distributors. Financial performance is therefore driven by prescription volume, channel pricing, supply continuity, formulation differentiation, and manufacturing cost.
What is the FDA status of doxepin hydrochloride?
The FDA has approved doxepin hydrochloride in multiple dosage forms and strengths.
| Product category |
Representative dosage form |
FDA use |
Commercial status |
| Oral doxepin hydrochloride |
Capsules, commonly 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, and 150 mg |
Depression and anxiety |
Generic, mature market |
| Low-dose oral doxepin |
Tablets, 3 mg and 6 mg |
Insomnia characterized by difficulty maintaining sleep |
Generic and branded-history market |
| Topical doxepin hydrochloride |
Cream, 5% |
Short-term treatment of pruritus associated with atopic dermatitis or lichen simplex chronicus |
Generic dermatology market |
The original oral doxepin product was commercialized as Sinequan. The low-dose insomnia product was marketed as Silenor by Somaxon Pharmaceuticals and later associated with Pernix Therapeutics. The topical product has been marketed under names including Zonalon and Prudoxin, with generic versions available.
The FDA-approved pharmacology is different across these markets. At antidepressant doses, doxepin is a tricyclic antidepressant with substantial noradrenergic and serotonergic activity. At 3 mg and 6 mg, the insomnia product is positioned primarily as an H1 histamine antagonist. Topical doxepin is used for local antipruritic activity but can produce systemic absorption and sedation.
When does doxepin hydrochloride lose exclusivity?
Doxepin hydrochloride lost meaningful market exclusivity many years ago. The original active-ingredient, formulation, and use patents associated with early oral products are expired or commercially immaterial.
| Exclusivity type |
Current position |
| Original molecule protection |
Expired |
| Original oral antidepressant product |
Generic competition established |
| Low-dose insomnia exclusivity |
FDA regulatory exclusivity expired |
| Topical 5% cream exclusivity |
Generic competition established |
| Current core composition patent |
No commercially significant protection identified |
| FDA generic pathway |
ANDA approval is available for qualifying products |
Silenor received FDA approval in March 2010. Its new-drug exclusivity period expired after the standard period applicable to a new indication and formulation. Generic doxepin tablets and other low-dose products subsequently entered the market, removing the principal commercial barrier to substitution.[1]
The commercial issue is no longer whether a manufacturer can enter the molecule. The issue is whether it can obtain adequate margins in a market with multiple approved products and limited clinical differentiation.
What patents protect doxepin hydrochloride products?
The original doxepin molecule and conventional oral formulations have no effective blocking patent estate. Any remaining patent analysis must distinguish between the active ingredient, dosage form, manufacturing process, and method of use.
Composition and active-ingredient patents
Doxepin was developed decades ago. Patents covering the compound and its earliest pharmaceutical uses have expired. A generic manufacturer does not face a meaningful composition-of-matter barrier for conventional doxepin hydrochloride capsules or tablets.
Formulation patents
Low-dose doxepin for insomnia was the principal formulation-driven commercial opportunity. Silenor used 3 mg and 6 mg tablets with a dosing strategy distinct from antidepressant-strength doxepin. Any historical patents covering low-dose use, tablet formulation, or treatment of sleep-maintenance insomnia have either expired, been rendered commercially nonblocking by generic approvals, or lack sufficient scope to prevent ordinary generic competition.
Method-of-use patents
The main method-of-use distinction was the treatment of insomnia with low-dose doxepin. The FDA approval created a separate product positioning strategy but did not preserve long-term exclusivity. Method-of-use claims can still affect the scope of an ANDA through the FDA’s Paragraph IV and section viii mechanisms, but they do not restore molecule-level exclusivity.
Manufacturing and process patents
Manufacturing know-how may remain commercially relevant even where patents are expired. Key cost variables include:
- Control of doxepin hydrochloride polymorphic form and particle properties
- Consistent low-dose tablet content uniformity
- Stability and impurity control
- Topical cream homogeneity
- Packaging that limits degradation and preserves shelf life
- Reliable production of low-volume strengths
These factors can create operational barriers without creating enforceable market exclusivity.
What is the Orange Book status of doxepin hydrochloride?
The FDA Orange Book distinguishes approved reference products from their patents and therapeutic-equivalence ratings. Doxepin products have separate regulatory histories depending on strength, dosage form, and indication.
| Reference-product history |
Orange Book relevance |
| Sinequan and equivalent oral products |
Mature reference-product and generic market |
| Silenor 3 mg and 6 mg tablets |
Separate low-dose insomnia reference product |
| Zonalon or Prudoxin 5% cream |
Topical reference-product history |
| Generic capsules and tablets |
Typically approved through ANDA pathways |
| Generic topical cream |
Approval depends on formulation and therapeutic-equivalence requirements |
Orange Book listing does not mean that a listed patent remains commercially blocking. A patent may be expired, delisted, or limited to a method of use. The practical assessment requires matching the listed patent to the specific dosage form and ANDA certification.
How many patents cover doxepin hydrochloride today?
No meaningful active patent portfolio covers the conventional doxepin hydrochloride molecule itself. The relevant patent count is therefore less important than product-specific listing status.
The practical estate can be summarized as follows:
| Patent category |
Commercial strength |
| Doxepin hydrochloride composition patents |
None remaining as a meaningful barrier |
| Conventional oral capsule patents |
None of strategic importance |
| Low-dose insomnia formulation patents |
Historical protection; generic competition established |
| Insomnia method-of-use patents |
Limited residual impact |
| Topical cream formulation patents |
Limited protection against established generics |
| Process and manufacturing patents |
Potentially useful for cost or quality, not market exclusion |
For investment and licensing analysis, doxepin should be classified as a low-patent-strength asset. Value depends on supply, contracting, product quality, and channel access.
Which companies are challenging doxepin hydrochloride exclusivity?
Generic competition is already established. The market includes large generic manufacturers, specialty suppliers, contract manufacturers, and private-label distributors. Publicly available data do not support a single definitive list of all current suppliers because FDA approvals, wholesaler listings, and commercial availability change by strength and dosage form.
Relevant competitive groups include:
- Large U.S. generic companies supplying oral capsules or tablets
- Specialty generic manufacturers supplying low-dose insomnia tablets
- Dermatology-focused companies supplying 5% cream
- Authorized distributors and private-label pharmacy suppliers
- Compounding pharmacies, which may affect niche demand but do not have the same role as FDA-approved generic manufacturers
The most important competitive distinction is dosage form. A company active in antidepressant-strength capsules is not automatically a competitor in 3 mg or 6 mg insomnia tablets, and a topical cream supplier competes through dermatology channels rather than the general antidepressant market.
What generic entry risks exist for doxepin hydrochloride?
Generic entry risk is already realized rather than prospective for conventional doxepin. The remaining risk is price erosion and supply substitution.
Oral antidepressant market
The oral capsule market has the highest generic maturity. Buyers can substitute among approved suppliers where therapeutic equivalence and availability permit. Price competition is intense, and low-volume strengths may experience intermittent supply constraints.
Low-dose insomnia market
The 3 mg and 6 mg products have more defensible commercial positioning because they target a separate prescribing behavior. That distinction does not create durable patent protection. Generic entry can reduce prices, weaken branded retention, and shift prescriptions toward payer-preferred products.
Topical dermatology market
The 5% cream market can retain better unit economics than standard oral capsules because dermatology products often have higher acquisition prices and less direct pharmacy substitution. The market remains exposed to generic competition, payer controls, and substitution by other antipruritic therapies.
What is the financial trajectory for doxepin hydrochloride?
Doxepin has a mature, low-growth financial profile at the molecule level. Revenue is divided among many companies, so no consolidated doxepin market revenue is reported in public filings.
Revenue drivers
The strongest revenue drivers are:
- Prescription volume in insomnia and dermatology.
- Number of active generic suppliers.
- Pharmacy benefit manager reimbursement.
- Product availability by strength.
- Manufacturer participation in government and institutional contracts.
- Formulation-specific pricing.
- Stock-outs affecting competitors.
Margin profile
Conventional oral capsules generally have low margins because manufacturing is established and substitution is easy. Margins can improve temporarily when competitors exit, a supplier experiences manufacturing problems, or a low-volume strength has limited availability.
Low-dose tablets can generate better unit economics than antidepressant-strength capsules when a supplier maintains brand recognition, distribution access, or an authorized-generic relationship. Those advantages tend to weaken as additional suppliers enter.
Topical 5% cream can have the strongest pricing potential, but its economics are sensitive to formulation complexity, dermatology payer restrictions, and competition from corticosteroids, antihistamines, calcineurin inhibitors, and newer antipruritic therapies.
Financial trajectory by segment
| Segment |
Near-term outlook |
Medium-term outlook |
| Oral antidepressant capsules |
Stable to declining pricing |
Mature, low-margin generic market |
| 3 mg and 6 mg insomnia tablets |
Volume supported by insomnia prescribing |
Price erosion as generic supply expands |
| 5% topical cream |
Potentially higher price per prescription |
Stable niche with payer and substitution pressure |
| New branded doxepin products |
Limited opportunity without differentiation |
Requires delivery, combination, or indication innovation |
The market is unlikely to produce substantial molecule-wide revenue growth without a new delivery system, a differentiated formulation, or a new approved indication.
How does doxepin compare with competing insomnia drugs?
Doxepin competes in insomnia with generic trazodone, zolpidem, eszopiclone, ramelteon, suvorexant, lemborexant, daridorexant, and over-the-counter sedating antihistamines.
| Drug |
Main market position |
Patent and pricing profile |
| Doxepin 3 mg/6 mg |
Sleep-maintenance insomnia |
Generic, low patent strength |
| Zolpidem |
Broad insomnia use |
Mature generic market |
| Eszopiclone |
Sleep-onset and maintenance |
Generic market |
| Trazodone |
Off-label insomnia use |
Generic, very low price |
| Ramelteon |
Melatonin-receptor approach |
Generic competition |
| Suvorexant |
Orexin antagonist |
Brand and patent-dependent economics |
| Lemborexant |
Orexin antagonist |
Higher branded pricing and exclusivity exposure |
| Daridorexant |
Orexin antagonist |
Brand-led market with patent value |
Doxepin’s commercial advantage is low cost and a differentiated mechanism at low doses. Its disadvantages are limited promotional support, sedation concerns, and strong competition from inexpensive generic alternatives.
What patent litigation and Paragraph IV activity affect doxepin?
Doxepin is not associated with an active, high-value patent litigation campaign comparable to major branded small-molecule products. Historical disputes around low-dose insomnia products were relevant during the transition from Silenor exclusivity to generic entry, but the market has moved beyond the central litigation phase.
Paragraph IV certifications may have been used for generic low-dose products when Orange Book patents were listed. Those certifications can trigger Hatch-Waxman litigation and a potential 30-month stay. The existence of a historical Paragraph IV case does not indicate current exclusivity, particularly where generic approvals have already been granted.
Current commercial risk is primarily operational:
- FDA inspection findings
- Manufacturing interruptions
- Drug shortages
- Contract loss
- Wholesaler delisting
- Pricing undercutting
- Product recalls
- Inability to support multiple tablet strengths
What licensing deals affect doxepin hydrochloride?
No major active licensing transaction currently defines the doxepin hydrochloride market. The most important historical transaction was the transfer of commercial control associated with Silenor after Somaxon’s development and commercialization efforts. Pernix Therapeutics later held commercial rights connected with the product.
The absence of a major current licensing market reflects the product’s generic status. A licensing transaction would need to rely on one of four assets:
- A proprietary delivery system
- A differentiated topical formulation
- A new indication
- A geographic commercialization right with established distribution
A license covering ordinary doxepin hydrochloride tablets would have limited strategic value unless it included manufacturing capacity, regulatory approvals, or protected market access.
What geographic markets offer the greatest opportunity?
The United States has the clearest regulatory and reimbursement structure but also intense generic competition. Europe and other developed markets have similarly mature tricyclic and insomnia markets, with pricing shaped by national reimbursement systems.
Potentially stronger opportunities exist in markets where:
- Low-dose insomnia products have limited availability
- Topical doxepin is underdistributed
- Local manufacturing capacity is constrained
- Regulatory approval can be obtained with limited clinical development
- Pharmacy substitution is less aggressive
- A manufacturer can bundle doxepin with a broader dermatology or CNS portfolio
Geographic expansion is more likely to produce incremental volume than premium pricing.
How strong is the doxepin hydrochloride patent estate?
The patent estate is weak. Doxepin is commercially viable as a generic product, but it is not an attractive asset for patent-protected pharmaceutical investment.
| Criterion |
Assessment |
| Composition protection |
Exhausted |
| Formulation protection |
Limited and largely historical |
| Method-of-use protection |
Narrow residual value |
| Generic entry barrier |
Low |
| Litigation exposure |
Low relative to active branded products |
| Manufacturing barrier |
Moderate for quality and supply reliability |
| Pricing power |
Low for oral products; moderate for topical products |
| Strategic value |
Distribution and formulation dependent |
The strongest defensible position would come from manufacturing reliability, a scarce dosage form, a specialized topical product, or a new delivery platform. Patent ownership alone is unlikely to support premium valuation.
Key Takeaways
- Doxepin hydrochloride is a mature generic drug with no meaningful active composition-patent barrier.
- The market consists of oral antidepressant products, low-dose insomnia tablets, and 5% topical cream.
- Conventional oral products have low pricing power and high substitution risk.
- Low-dose insomnia products retain some commercial differentiation but not durable molecule-level exclusivity.
- Topical cream can generate better unit economics than oral capsules, although payer and generic competition remain significant.
- No consolidated public revenue figure exists for doxepin hydrochloride because sales are fragmented across suppliers.
- The principal financial risks are price erosion, supply interruption, wholesaler access, and generic substitution.
- The most credible growth strategy is formulation, delivery, dermatology specialization, or geographic expansion rather than reliance on the legacy molecule.
Frequently Asked Questions
Is doxepin hydrochloride still patented?
The original molecule and conventional oral products are no longer protected by commercially meaningful patents. Historical patents related to low-dose insomnia formulations and methods of use have not prevented generic competition.
Is Silenor still an exclusive product?
No. Silenor’s historical regulatory exclusivity has expired, and generic low-dose doxepin products are available or have been approved.
Is doxepin hydrochloride a profitable generic drug?
Profitability depends on dosage form and supply conditions. Standard capsules are typically low-margin. Low-dose tablets and topical cream can produce better economics when competition is limited or supply is constrained.
Does doxepin hydrochloride have biosimilar risk?
No. Doxepin hydrochloride is a chemically synthesized small molecule, not a biologic. The relevant competitors are generic drugs, not biosimilars.
Can a new company obtain FDA approval for doxepin hydrochloride?
Yes. A manufacturer can pursue an ANDA for a qualifying generic product or a 505(b)(2) application for a materially differentiated formulation, indication, or delivery system.
References
-
U.S. Food and Drug Administration. (2010). Silenor (doxepin hydrochloride) prescribing information. Drugs@FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.
-
U.S. Food and Drug Administration. (2024). Doxepin hydrochloride capsule prescribing information. DailyMed.
-
U.S. Food and Drug Administration. (2024). Doxepin hydrochloride cream, 5%, prescribing information. DailyMed.
-
U.S. Food and Drug Administration. (2024). Hatch-Waxman amendments and abbreviated new drug application approvals. Center for Drug Evaluation and Research.
